SCHEMBL10004644

SCHEMBL10004644

CCOC(=O)c1c(OCC(F)(F)F)c2cc(-c3ccc(F)nc3)c(CC)nc2n1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.37
▸ GAA P10253 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ SCN9A Q15858 3/20 0.36
▸ MAPT P10636 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ GABRA2 P47869 1/20 0.34
▸ GABRB2 P47870 1/20 0.34
▸ KDM4E B2RXH2 5/20 0.34
▸ HPGD P15428 4/20 0.34
▸ LMNA P02545 1/20 0.34
▸ CSNK1D P48730 1/20 0.34
▸ METAP2 P50579 1/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CASP1 P29466 1/20 0.34
▸ CASP7 P55210 1/20 0.34
▸ SCN5A Q14524 1/20 0.34
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003348 0.91 ALDH1A1 (0.44) ALDH1A1GAAL3MBTL1MAPTGABRA2
SCHEMBL10003955 0.90 ALDH1A1 (0.40) ALDH1A1GAAL3MBTL1MAPTPOLB
SCHEMBL10003659 0.90 RXRA (0.35) L3MBTL1SCN9ASCN5APIK3CA
SCHEMBL10003298 0.90 ALDH1A1 (0.37) ALDH1A1GAAL3MBTL1MAPTPOLB
SCHEMBL10003344 0.90 PIK3CA (0.45) ALDH1A1GAAMAPTPOLBPIK3CA
SCHEMBL10003637 0.89 MAPT (0.40) ALDH1A1GAAL3MBTL1MAPTKDM4E
SCHEMBL10004342 0.89 CSNK1D (0.43) ALDH1A1GAAL3MBTL1MAPTPOLB
SCHEMBL10004077 0.88 GABRA2 (0.41) ALDH1A1GAAL3MBTL1MAPTPOLB
SCHEMBL10003156 0.88 KDM4E (0.41) ALDH1A1GAAMAPTGABRA2GABRB2
SCHEMBL12003592 0.88 POLB (0.42) ALDH1A1GAAL3MBTL1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH ALDH1A1 321/4885GAA 3144/4885L3MBTL1 2806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback